| Q90100849 | A common variant of the pregnancy-associated plasma protein-A (PAPPA) gene encodes a protein with reduced proteolytic activity towards IGF-binding proteins |
| Q38170863 | A historical and practical review of first trimester aneuploidy screening |
| Q33721476 | A review of risk factors for child pedestrian injuries: are they modifiable? |
| Q71598362 | A sensitive enzyme immunoassay for pregnancy-associated plasma protein A (PAPP-A): a possible first trimester method of screening for Down syndrome and other trisomies |
| Q37765287 | A timely diagnosis of myocardial infarction. |
| Q43828982 | Accuracy of single measurements of pregnancy-associated plasma protein-A, human chorionic gonadotropin and progesterone in the diagnosis of early pregnancy failure |
| Q40909255 | Antenatal screening for Down's syndrome. |
| Q37801660 | Application of proteomics to prenatal screening and diagnosis for aneuploidies. |
| Q52208776 | Appropriate biochemical parameters in first-trimester screening for Down syndrome. |
| Q43152691 | Biochemical screening for Down's syndrome |
| Q74132225 | Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland |
| Q58136234 | First Trimester Biochemical Screening for Down's Syndrome |
| Q38893745 | First trimester combined screening - focus on early biochemistry. |
| Q33768998 | First trimester screening for aneuploidy: serum biochemical markers |
| Q37208068 | First- and second-trimester Down syndrome screening: current strategies and clinical guidelines. |
| Q45291831 | First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. |
| Q71620967 | First-trimester biochemical screening for Down syndrome with the use of PAPP-A, AFP, and beta-hCG |
| Q72080653 | Low maternal serum levels of pregnancy associated plasma protein A (PAPP‐A) in the first trimester in association with abnormal fetal karyotype |
| Q73070410 | Markers for Down's syndrome in early pregnancy |
| Q42762495 | Pregnancy associated plasma protein A in Down's syndrome |
| Q42984383 | Pregnancy associated plasma protein A in Down's syndrome |
| Q84836506 | Prenatal testing for Down syndrome: comparison of screening practices in the UK and USA |
| Q36624223 | Present and future biochemical markers for detection of acute coronary syndrome |
| Q55014471 | Prognostic value of the Stanniocalcin-2/PAPP-A/IGFBP-4 axis in ST-segment elevation myocardial infarction. |
| Q41199161 | Screening for Down's syndrome |
| Q72099390 | Serum PAPP‐A levels are depressed in women with fetal Down syndrome in early pregnancy |
| Q40584410 | Techniques in current use in prenatal diagnosis. |
| Q37470283 | The ethics of antenatal screening: lessons from Canute. |
| Q90539086 | The insulin-like growth factor-1 system in the adult mammalian brain and its implications in central maternal adaptation |
| Q73083969 | The proform of eosinophil major basic protein: a new maternal serum marker for Down syndrome |
| Q35690633 | The role of PAPP-A in the IGF system: location, location, location. |